The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Ischemic Preconditioning and Brain Tolerance: Temporal Histological and Functional Outcomes, Protein Synthesis Requirement, and Interleukin-1 Receptor Antagonist and Early Gene Expression
Abstract
Background and Purpose —A short duration of ischemia (ie, ischemic preconditioning [PC]) can provide significant brain protection to subsequent ischemic events (ie, ischemic tolerance [IT]). The present series of studies was conducted to characterize the temporal pattern of a PC paradigm, to systematically evaluate the importance of protein synthesis in PC-induced IT, and to explore candidate gene expression changes associated with IT. Methods —Temporary middle cerebral artery occlusion (MCAO) (10 minutes) was used for PC. Various periods of reperfusion (ie, 2, 6, and 12 hours and 1, 2, 7, 14, and 21 days) were allowed after PC and before permanent MCAO (PMCAO) (n=7 to 9 per group) to establish IT compared with non-PC (sham-operated) rats (n=22). Infarct size, forelimb and hindlimb motor function, and cortical perfusion (laser-Doppler flowmetry; n=9 per group) were measured after PMCAO. The effects of the protein synthesis inhibitor cycloheximide administered just before PC (n=13 to 17) or administered long after PC but just before PMCAO (n=7 to 8) on IT were also determined. Interleukin-1 receptor antagonist mRNA (reverse transcriptase and polymerase chain reactions [n=20] and Northern analysis [n=50]) and protein expression (immunohistochemistry [n=16]) after PC and early response gene expression (Northern analysis [n=16]) after PMCAO in PC animals were determined. Results —Hemispheric infarct was significantly ( P <0.01) reduced only if PC was performed 1 day (decreased 58.4%), 2 days (decreased 58.1%), or 7 days (decreased 59.4%) before PMCAO. PC significantly ( P <0.01) reduced neurological deficits (similar to reductions in infarct size). Cycloheximide eliminated ischemic PC–induced IT effects on both brain injury and neurological deficits if administered before PC ( P <0.05) but not if administered long after PC but before PMCAO. PC did not produce any significant brain injury, alter cortical blood flow after PMCAO, or produce contralateral cortical neuroprotection. Interleukin-1 receptor antagonist mRNA and protein expression were increased significantly ( P <0.01) only during the IT period. PC rats also exhibited a significant ( P <0.01) reduction in c- fos and zif268 mRNA expression after PMCAO. Conclusions —PC is a powerful inducer of ischemic brain tolerance as reflected by preservation of brain tissue and motor function. PC induces IT that is dependent on de novo protein synthesis. New protein(s) that occurs at the PC brain site 1 to 7 days after PC contributes to the neuroprotection. Those proteins that are produced after the more severe PMCAO in PC animals apparently do not contribute to IT. The PC-induced IT is also associated with increased expression of the neuroprotective protein interleukin-1 receptor antagonist and a reduced postischemic expression of the early response genes c- fos and zif268.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular chaperones in cellular protein folding
Hartl, F. U. (1996) · Nature · doi:10.1038/381571a0 · Cited by 3,568
Morgan, J. I., & Curran, T. (1991) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.14.030191.002225 · Cited by 2,711
Expression of c- fos Protein in Brain: Metabolic Mapping at the Cellular Level
Sagar, S. M., Sharp, F. R., & Curran, T. (1988) · Science · doi:10.1126/science.3131879 · Cited by 1,925
A Semiautomated Method for Measuring Brain Infarct Volume
Swanson, R. A., Morton, M. T., Tsao-Wu, G., Savalos, R. A., Davidson, C., & Sharp, F. R. (1990) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1990.47 · Cited by 1,644
Fos and jun: The AP-1 connection
Curran, T., & Franza, B. R. (1988) · Cell · doi:10.1016/0092-8674(88)90024-4 · Cited by 1,567
‘Ischemic tolerance’ phenomenon found in the brain
Kitagawa, K., Matsumoto, M., Tagaya, M., Hata, R., Ueda, H., Niinobe, M., Handa, N., Fukunaga, R., Kimura, K., Mikoshiba, K., et al. (1990) · Brain Research · doi:10.1016/0006-8993(90)90189-i · Cited by 1,091
Hara, H., Friedlander, R. M., Gagliardini, V., Ayata, C., Fink, K., Huang, Z., Shimizu-Sasamata, M., Yuan, J., & Moskowitz, M. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.2007 · Cited by 834
Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro
Dinarello, C. A., & Thompson, R. C. (1991) · Immunology Today · doi:10.1016/0167-5699(91)90142-g · Cited by 724
Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats.
Lin, T. N., He, Y. Y., Wu, G., Khan, M., & Hsu, C. Y. (1993) · Stroke · doi:10.1161/01.str.24.1.117 · Cited by 722
Very Delayed Infarction after Mild Focal Cerebral Ischemia: A Role for Apoptosis?
Du, C., Hu, R., Csernansky, C. A., Hsu, C. Y., & Choi, D. W. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199603000-00003 · Cited by 600
Cited by
Ischemic Cell Death in Brain Neurons
Lipton, P. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1431 · Cited by 3,043
Aloisi, F. (2001) · Glia · doi:10.1002/glia.1106 · Cited by 1,280
Inflammatory Mediators and Stroke: New Opportunities for Novel Therapeutics
Barone, F. C., & Feuerstein, G. Z. (1999) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199908000-00001 · Cited by 930
Self-citationdel Zoppo, G., Ginis, I., Hallenbeck, J. M., Iadecola, C., Wang, X., & Feuerstein, G. Z. (2000) · Brain Pathology · doi:10.1111/j.1750-3639.2000.tb00247.x · Cited by 662
Self-citationDirnagl, U., Becker, K., & Meisel, A. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70054-7 · Cited by 587
Metadata
- Authors
- Barone, F. C., White, R. F., Spera, P. A., Ellison, J., Currie, R. W., Wang, X., & Feuerstein, G. Z.
- Venue
- Stroke
- Published
- 1998-09
- Volume
- 29
- Issue
- 9
- Pages
- 1937-1951
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2099816146
- Cited by
- 486
- References
- 82
- FWCI
- 17.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ischemic Preconditioning and Brain Tolerance: Temporal Histological and Functional Outcomes, Protein Synthesis Requirement, and Interleukin-1 Receptor Antagonist and Early Gene Expression. https://app.cochat.ai/papers/10.1161/01.str.29.9.1937
- The paper
- Barone, F. C., White, R. F., Spera, P. A., Ellison, J., Currie, R. W., Wang, X., & Feuerstein, G. Z. (1998). Ischemic Preconditioning and Brain Tolerance: Temporal Histological and Functional Outcomes, Protein Synthesis Requirement, and Interleukin-1 Receptor Antagonist and Early Gene Expression. Stroke. https://doi.org/10.1161/01.str.29.9.1937
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.